Kenneth Moch has resigned as chief executive of the biopharmaceutical company to "pursue other interests," the company announced on Wednesday while also naming his replacement.
Updated March 19
A spate of Triangle life science IPOs raised more total money than those in Boston and New York in 2013, and more followed early this year. Has this open IPO window affected biotech and life science fundraising in the Triangle? Will the window remain open? One area VC suggests we may look back on 2010-2015 as a watershed time for the regional industry.
Chimerix, the Durham-based drug company working on experimental medicine that could save the life of a seven-year-old Virginia child, was granted approval by the U.S. Food and Drug Administration to administer the drug to the boy, the company said Tuesday evening.
Updated February 28
Quintiles led the class of Triangle IPOs in the last year at nearly $1 billion in value, but ChannelAdvisor's stock is showing remarkable strength. So is Aerie Pharmaceuticals. With Scynexis filing to go public Thursday, WRALTechWire updates what has happened on the stock "exit route" for regional firms and how their stocks have fared since.
Updated October 25, 2013
Aerie Pharmaceuticals' $67 million IPO was priced at $10 per share, well below the $12 to $14 per share range the company had previously set. Read more about the offering.
October 8, 2013
Chimerix, a Durham-based drug developer that went public in April for more than $100 million, says in an SEC filing that "certain stockholders" are looking to sell their shares.
May 13, 2013
The company, which went public in April, reports a drop in revenue and an increase in expenses. But stock rallies 4 percent on the news.
March 14, 2013
Updated December 10, 2012
Finding the right chemistry is crucial to biotech deals, as two major life science partnerships in the Triangle have shown this year: GSK and Liquidia; Merck and Chimerix.
November 12, 2012
Dr. Michelle Berrey, MD, joins the firm from Pharmasset where she also served as CMO. Pharmasset was acquired by Gilead Sciences earlier this year.
July 25, 2012
In exchange for exclusive worldwide license and funding the drug development and commercialization costs, Merck will pay Chimerix $17.5 million on top of royalties on future sales and milestone payments of up to $151 million.
February 7, 2012
The company is studying the compound for the prevention of cytomegalovirus diseases, or CMV, in patients who have had stem cell transplants.
June 28, 2011
Chimerix fought the award of a sole-source contract for a potential smallpox treatment to another firm and convinces the government agency involved to overturn it. Now, Chimerix can compete for a lucrative deal, CEO says.
February 17, 2011
Under the terms of this BARDA contract, Chimerix potentially could net almost $81.1 million total.
February 14, 2011
New funding is aimed at further development of vitally important new antiviral medicines for the treatment of life-threatening diseases.
May 7, 2010
The biotechnology firm recently reshuffled its management team, board.
May 4, 2010
The company, which is developing antiviral treatments that can be taken orally, promotes its chief operating officer to top post. Its former CEO is now chief science officer.